Science chief at NIH drug abuse institute resigned after sexual misconduct probe

In August, Antonello Bonci, scientific director of the National Institute on Drug Abuse (NIDA), resigned, and the agency’s director told employees in an email that Bonci would be running an addiction institute in Florida. Science has learned that Bonci’s departure followed an investigation spurred by an internal complaint, which alleged that he sexually targeted a trainee and later directed resources to another trainee with whom he was in an intimate relationship. Sources at the National Institutes of Health (NIH), which NIDA is part of, said they were disturbed by NIDA’s…

Read More

The Loopholes Drug Companies Use to Keep Prices High

The retired firefighter, 53, needs Revlimid to stay healthy. Celgene Corp. has raised the price 88 percent over the past seven years. The drug doesn’t have substantial competition from a less expensive generic version, and probably won’t for another eight years. Celgene has worked hard to make sure of that. Drugmakers typically have exclusive rights to sell brand-name medicines for 12 or 13 years. After that, cheaper copycats can hit the market. Celgene and a growing number of other pharmaceutical giants are taking advantage of an array of loopholes to extend the exclusivity period,…

Read More

Cancer drug prices must come down, say leading research institutes

The high price of new cancer drugs is indefensible and unsustainable, say two of the world’s leading cancer research institutions, who propose a different way to develop them that could sideline big pharma. “There is a clear and urgent necessity to lower cancer drug prices to keep lifesaving drugs available and affordable to patients,” say leading scientists from the Institute of Cancer Research in the UK and the University of Texas MD Anderson Cancer Center, where many important new cancer drugs have been invented, in a paper in the journal…

Read More